Abstract:Cytochrome P450s CYP1A1 and CYP1A2 can metabolize a broad range of foreign compounds and drugs. However, these enzymes have significantly overlapping substrate specificities. To establish their relative contribution to drug metabolism in vivo, we used a combination of mice humanized for CYP1A1 and CYP1A2 together with mice nulled at the Cyp1a1 and Cyp1a2 gene loci. CYP1A2 was constitutively expressed in the liver, and both proteins were highly inducible by 2,3,7,8-tetrachlorodibenzodioxin (TCDD) in a number of tissues, including the liver, lung, kidney, and small intestine. Using the differential inhibition of the human enzymes by quinidine, we developed a method to distinguish the relative contribution of CYP1A1 or CYP1A2 in the metabolism of drugs and foreign compounds. Both enzymes made a significant contribution to the hepatic metabolism of the probe compounds 7-methoxy and 7-ehthoxyresorufin in microsomal fractions from animals treated with TCDD. This enzyme kinetic approach allows modeling of the CYP1A1, CYP1A2, and non-CYP1A contribution to the metabolism of any substrate at any substrate, inhibitor, or enzyme concentration and, as a consequence, can be integrated into a physiologically based pharmacokinetics model. The validity of the model can then be tested in humanized mice in vivo.SIGNIFICANCE STATEMENTHuman CYP1A1 and CYP1A2 are important in defining the efficacy and toxicity/carcinogenicity of drugs and foreign compounds. In light of differences in substrate specificity and sensitivity to inhibitors, it is of central importance to understand their relative role in foreign compound metabolism. To address this issue, we have generated mice humanized or nulled at the Cyp1a gene locus and, through the use of these mouse lines and selective inhibitors, developed an enzyme kinetic-based model to enable more accurate prediction of the fate of new chemicals in humans and which can be validated in vivo using mice humanized for cytochrome P450–mediated metabolism.

[Heterogeneous expression of human CYP and its application in early stage of new drug research and development].

Investigation on Modulation of Human Cytochrome P450 and P-glycoprotein by Herb or Natural Product Using in Vivo Probe Substrate

Expression and Characterization of Human Cytochrome P450 1A2

Study Heterogenous Expression and Activity Determination of Human Cytochrome P450 2B6

Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication

Expressing in Vitro and Functional Study of Human CYP2D6 Gene

Advancement of Mammalian CYP450s Expression in E.coli

Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.

Quantitative Analysis of Cytochrome P450 Isoforms in Human Liver Microsomes by the Combination of Proteomics and Chemical Probe-Based Assay

Cloning of Human Cytochrome P450 2A6 Cdna and Its Expression in Mammalian Cells

Advances in Human Cytochrome P450 and Personalized Medicine

Drugs As CYP3A Probes, Inducers, and Inhibitors

Cytochrome P450 Reaction-Phenotyping: an Industrial Perspective

Establishment of a Yeast System That Stably Expresses Human Cytochrome P450 Reductase: Application for the Study of Drug Metabolism of Cytochrome P450s in Vitro.

Cytochrome P450 Enzymes and Drug Metabolism in Humans

Structure of cytochrome p450s and personalized drug.

Computational Identification of the Paralogs and Orthologs of Human Cytochrome P450 Superfamily and the Implication in Drug Discovery

Engineering of Human CYP3A Enzymes by Combination of Activating Polymorphic Variants

Establishment of the Recombinant Human Cytochrome P450 2C9 Saccharomyces Cerevisiae Expression Systems in Vitro and the Impact of Gene Polymorphism on Drug-Drug Interactions

A CYP2B6-humanized mouse model and its potential applications

Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice